UltraTech Cement Ltd. is the largest manufacturer of grey cement, Ready Mix Concrete (RMC) and white cement in India. It is also one of the leading cement producers globally. The company has a consolidated capacity of 117.35 Million (including Bara) Tonnes Per Annum (MTPA) of grey cement. UltraTech Cement has 23 integrated plants, 1 clinkerisation plant, 27 grinding units and 7 bulk terminals, post the Century merger. Its operations span across India, UAE,...

Dr Reddy's Laboratories has been catering to the needs of the pharmaceutical sector for over two decades. Active Pharmaceutical Ingredients (API) are their core strength, having a wide range of portfolio. The company also manufactures generic medicines with business spread across India, Russia, US and Germany as well as Proprietary Products which includes NCE research, biologics business and differentiated formulations conducted in the US. Under this the...

Downside risks: delay in resolution of Dahej (OAI) and Indrad (WL), slower growth in India and launch delays in the US. We resume coverage on Torrent Pharma (TRP) with a Buy. Torrent has re-rated substantially in the past three years on the back of strong execution particularly in branded markets. Despite rich valuation, we recommend Buy as TRP offers a solid India franchise, robust earnings growth and superior return profile which justifies the premium over peers. TRP would generate Rs56bn of FCF over FY19-22E. Our TP of Rs 2,250 is based on 15x FY22 EV/EBIDTA implying a target PE of 28x.

We re-iterate our Buy on Indigo as (1) The carrier will benefit from improving industry dynamics in the medium term. Air India has once again been put up for divestment by the GoI (2) Crude prices remain benign which will allow for better cost management. Efficiency gains from the Neo fleet will further benefit (3) Valuations at current levels (6.7/4.9x FY21/22E EV/EBITDAR) are undemanding. Any resolution of the ongoing dispute amongst the two promoters will lead to a re-rating of the stock. IndiGos 3QFY20 results were ahead of expectations - the demand environment improved in Nov-Dec, post a soft October, which led to the earnings beat. The revenues grew ~25% YoY due to an improvement in yields (+10 QoQ) and higher ancillary revenues (+29% YoY). We roll forward and set a Dec-21 TP of Rs 1,750 (@6x EV/EBITDAR). Maintain BUY.

PEPL is going all out (1) On building lease assets & (2) Increasing Non-South exposure with JV/JD tie ups. It's banking on the consolidation theme and picking up distressed projects in non-south markets. Large capex outlays on new lease assets will be cash flow dilutive over next 3-4yrs and requires timely funding from existing lease assets monetization and deployment of capital in cash flow dilutive under construction projects. Office assets under construction/upcoming launches of 15/25mn sqft are aggressive with overall office portfolio expected to increase from 10mn sqft to 50mn sqft over next 5-6yrs. We retain NEU with increased (new leases addition) TP of Rs 358/sh. We maintain NEU on PEPL with SOTP of Rs 358/sh (vs. Rs 348/sh earlier). We have increased our FY20/21E EPS estimates by 35%/18.9% to factor in better than expected deliveries in residential projects. PEPL posted strong 3QFY20 results.

HDFC reported strong profitability higher than market estimates with stable loan growth and improvement in margins sequentially. PAT grew 3x YoY (1x QoQ) led by treasury gain on stake sale in Gruh. The Non-Individual book growth improved a bit to 6% vs 4% (Q2FY20), while Individual book grew ~16%. Despite the challenges in its core housing finance business, HDFC is able to garner its individual book and maintain asset quality at decent levels. We expect the same trend to continue and return ratios to improve once normalcy returns within the sector. Hence, we give ACCUMULATE rating on the stock with a SOTP based TP of Rs2,625 valuing parent business at Rs1,409 (3.1x...

Sonata's platformation strategy to provide IT services around IPs is yielding results. Growth in IP-led revenues is improving employee productivity and aiding margin expansion. Sonata is expanding Microsoft D365 platform and IP-led related services to new clients across verticals and geographies, which will drive growth. We like Sonata's IP-focussed business model, high RoE (~35%) and dividend yield of ~5%. The stock trades at a P/E of 11.0x FY21E, which is at 20% discount to Tier-2 IT median valuations. We expect IITS' USD revenue to grow 11.8/11.5% with margin of 23.3/23.7% in FY21/22E. Risks include deceleration in top-account, delay in collections and slowdown in US/Europe. We maintain BUY on Sonata based on strong performance in 3QFY20. IP-led strategy, strong Microsoft partnership and expansion of Microsoft D365 offerings is driving growth and aiding margin expansion in IT services business. DPS growth momentum will continue led by Microsoft and there is scope for margin expansion. We upgrade our FY22E Rev/EPS estimate by 6.1/5.1%. Our TP of Rs 422 is based on 12x (~4% premium to 5Y avg.) Dec-21E EPS.

Our estimates remain largely unchanged, even after DCBB's soft performance over 3QFY20. We model a considerable improvement in credit growth and operating efficiency beyond FY20E. These reflect our confidence in the bank's calibrated approach to growth. We expect oplev to be the biggest driver of return ratio improvement. DCBB stands to gain from an uptick in economic activity and a sustained downturn will pose a significant risk to our estimates. DCBB reported an in-line qtr and overall performance was lackluster (asset quality deterioration and slowing growth). Better cost control and a slight margin uptick were positives. MAINTAIN BUY with a TP of Rs 249.

Favourable structural changes at ICICIBC continue (better quality corporate underwriting, balance sheet retailisation and P&L fortification). While the pace of asset quality improvement may slow in the near term, as with some of its peers, the broader trajectory remains unchanged. Improving asset quality, moderating LLPs and better growth trends underpin our stance. A sustained improvement could trigger further re-rating. ICICBC reported an inline qtr across all parameters. PAT jumped on a/c of lower provisions. Reported asset quality improved slightly, as a result of higher recoveries, even as slippages saw a rise. The 8% QoQ rise in exposure to BB and below rated a/cs was not too surprising. Maintain BUY with an SoTP of Rs 587 (2.2x Dec-21E core ABV of Rs 202 and sub-value of Rs 142).

27 January 2020 Torrent Pharma (TRP) has exhibited a robust 23% CAGR (FY14-19) in domestic formulation (DF) sales, executing well both organically and inorganically. However, this benefit is getting offset to some extent by the ongoing regulatory issues at its Dahej/Indrad sites for the US generics business. We maintain our EPS estimate for FY20/21/22 to factor in better operating leverage in DF and increased market share in US generics. Maintain Neutral given the limited upside from current levels. India business (INR8.7b) grew by a moderate 4.3% (partly due to a high base of past year). Adjusting for one-offs due to the integration of TRP and Unichems stockists, India business growth stands at 8.5% YoY. Brazil business was up 12.5% YoY at INR1.9b. US business was down 22% YoY to INR3.

HDFC reported another quarter of consistent performance with healthy AUM growth of ~14% YoY, stable spreads of ~2.3% and largely flat GS3% of 1.6%. While NII grew 11% YoY, lower assignment income (INR1.7b v/s INR2.6b YoY), higher opex (+14% YoY) and provisions led to flat core PBT. We expect core RoAA of 1.9% and RoE Note that retail lending growth has remained healthy at 16- 18% with stable individual spreads of ~1.9% since the IL&FS; crisis. Over the past four quarters, HDFC has maintained steady retail loan growth of 16-17% YoY while curtailing wholesale disbursements the share of wholesale loans in overall AUM is down 200bp to 24%. We expect the company to largely maintain spreads as the cuts in home loan rates are offset by declining cost of funds and opportunistic non-individual loan growth. HDFC will continue to effectively We keep our earnings estimates largely unchanged and expect the company to report core PBT CAGR of ~10% over FY20-23.

27 January 2020 The renewed strategy in the US, the enhanced focus on branded generics in emerging markets and the cost-control initiatives are promising steps that bolster DRRDs earnings prospects. We raise our EPS estimate by 7.3%/8.2%/9.2% for FY20/21/22 to factor in the better outlook in India/Russia, the higher gross margin and the scope of enhancing operating leverage. 3QFY20, driven by all business segments (except the US which grew moderately by 8% YoY to INR16b 36% of sales). Pharmaceutical Services and Active Ingredients (PSAI) segment (16% of sales) grew at 16% YoY to INR6.9b. India business (17% of sales) was up 13% YoY at INR7.6b, while Europe business (7% of sales) grew by 52% YoY. Emerging markets (21% of sales) was up 19% YoY to INR9.2b, led by CIS (+26% YoY) and Russia (+20% YoY). Gross margin expanded 20bp YoY (+260bp QoQ) to 54.1% on an improved product mix.

Q2FY20) and exports accounted for 24% of shipments (31% in Q2FY20). The OPM decreased 860 bps to 13.6%. Thus the operating profit fell by 46% to Rs 2451 crore. Cost of material consumed as a percentage of adjusted net sales rose by 80 bps to 53.4%. Employee benefit expenses rose 110 bps to 4.1%. Power and fuel expenses remained flat at...

crore. After accounting gain of Rs 0.10 crore in Share in Profit of Associates and NIL in Minority interest, the Net Profit, as a result, grew by 81% to Rs 711.25 crore. Acquisition of Century's Cement Business The Scheme of Demerger for acquiring the cement business of Century Textiles and Industries Limited became effective from 1st October, 2019. The Company's financials were restated from...

Haryana, Himachal Pradesh, and Delhi. With the launch of Zee Punjabi, ZEEL's regional footprint has expanded to 9 languages. Movie channels - Zee Thirai and Zee Biskope, will enhance ZEEL's regional movie portfolio in the markets of Tamil Nadu and Bihar, respectively. The network is preparing for the launch of 2 more regional channels in the next few months. Our regional portfolio had mixed performance during the quarter. We maintained leadership position in the Marathi, Bangla and Kannada markets, with Zee Kannada further strengthening its leadership position, widening the gap over the nearest competitor. Viewership shares in Marathi and Bangla markets declined during the quarter. While Zee Tamil improved its viewership share, Zee...

As on 31st December 2019, the Bank's Gross NPA and Net NPA levels were 5.00% and 2.09% respectively, as against 5.03% and 1.99% respectively end September 2019. The Bank has recognized slippages of Rs 6214 crore during Q3FY20, compared to Rs 4983 crore in Q2FY20 and Rs 3746 crore in Q3FY19. Slippages from the loan book were at Rs 5124 crore and that from investment exposures stood at Rs 1090 crore. Corporate slippages stood at Rs 3891 crore. 81% of this came from previously disclosed BB and below rated clients (fund based loans, non-fund based loans and investment holdings)....

together with 40 bps expansion in operating profit margin to 11.4%, the operating profit was up by 10% to Rs 4117.72 crore. But with other income stand lower by 19% to RS 474.92 crore, the growth at PBIDT was restricted at 6% to Rs 4592.64 crore. But with interest and depreciation...

December 2019 compared to corresponding previous year period. The company operating margins rose 90 bps to 21.9%. As a result operating profit growth rose 8% to Rs 1189.39 crore. Cost of raw material consumed as a percentage of net sales (net of stock adjustment) fell 560 bps to 45.6% while purchase of stock in trade rose 140 bps to 8.3%, employee benefit expense rose 70 bps to 6.8% and other expense increased 140 bps to 15.8%....

Deal wins, digital, client mining key growth levers The company reported a sequential decline of 5.9% in dollar revenues in the quarter on the back of 13.4% QoQ drag in core revenues. This was primarily due to client specific ramp down in retail ($5 million) along with seasonal weakness and volume discount given to two clients. On the other hand, digital increased 1.6% QoQ and 20.2% YoY. Further, strong order booking of $170 million+ TCV with 45% as new wins and healthy pipeline coupled with consistent focus on client mining would lead revenues to grow at a...